Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1077 | 1051 | 1187 | 1099 | 1487 | 1582 |
Fund Return | 7.71% | 5.15% | 18.69% | 3.21% | 8.26% | 4.69% |
Place in category | 291 | 374 | 231 | 116 | 204 | 144 |
% in Category | 36 | 46 | 33 | 20 | 32 | 39 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Schwab S&P 500 Index | 94.87B | 11.27 | 9.53 | 12.63 | ||
Schwab Total Stock Market Index | 23.65B | 10.19 | 7.69 | 11.98 | ||
Schwab 1000 Index | 16.31B | 10.70 | 8.37 | 12.20 | ||
Schwab Fundamental US Large Company | 8.62B | 8.36 | 8.70 | 11.20 | ||
Schwab Small Cap Index | 5.91B | 2.71 | -1.59 | 7.72 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Intl Stock Index Inv | 197.89B | 6.01 | 0.42 | 4.22 | ||
Vanguard Total Intl Stock Index Adm | 75.61B | 6.04 | 0.47 | 4.29 | ||
Fidelity International Index Inst | 48.57B | 7.74 | 3.30 | 4.80 | ||
Fidelity Series Global ex US Index | 44.6B | 6.35 | 0.53 | 4.10 | ||
Vanguard Total Intl Stock Index I | 41.01B | 6.06 | 0.50 | 4.32 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 2.53 | 984.0 | +1.10% | |
ASML Holding | NL0010273215 | 2.12 | 958.90 | +0.15% | |
Nestle | CH0038863350 | 1.62 | 98.02 | -0.33% | |
Toyota Motor | JP3633400001 | 1.46 | 3,219.0 | -1.65% | |
AstraZeneca | GB0009895292 | 1.42 | 12,556.0 | -0.27% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review